A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial Evaluating the Efficacy and Safety of 2 Doses of Buloxibutid Over 52 Weeks in People With Idiopathic Pulmonary Fibrosis
Latest Information Update: 26 Jun 2025
At a glance
- Drugs Buloxibutid (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms ANDAS; ASPIRE
- Sponsors Vicore Pharma
Most Recent Events
- 26 Nov 2024 Planned initiation date (estimated date of first participant enrollment) changed from 1 Oct 2024 to 1 Dec 2024.
- 30 Sep 2024 Planned initiation date (estimated date of first participant enrollment) changed from 1 Sep 2024 to 1 Oct 2024.
- 30 Sep 2024 Status changed from not yet recruiting to recruiting.